Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4- dichlorophenyl)-2-methoxyethyl]piperidine and related compounds

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 15, 2013, Pages 4600-4613

  Ishichi, Yuji ^a   Kimura, Eiji ^a   Honda, Eiji ^a   Yoshikawa, Masato ^a   Nakahata, Takashi ^a   Terao, Yasuko ^a   Suzuki, Atsuko ^a   Kawai, Takayuki ^a   Arakawa, Yuuichi ^a   Ohta, Hiroyuki ^a   Kanzaki, Naoyuki ^a   Nakagawa, Hideyuki ^a   Terauchi, Jun ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Antidepressant; Cationic amphiphilic drug (CAD); CYP2D6; hERG; Monoamine reuptake inhibition; Piperidine compounds; PLsis; Tail suspension test

Indexed keywords

4 [1 (3,4 DICHLOROPHENYL) 2 METHOXYETHYL]PIPERIDINE; [1 (TERT BUTOXYCARBONYL)PIPERIDIN 4 YL](3 CHLORO 4 FLUOROPHENYL)ETHANOIC ACID; [1 (TERT BUTOXYCARBONYL)PIPERIDIN 4 YL](3 CHLOROPHENYL)ETHANOIC ACID; [1 (TERT BUTOXYCARBONYL)PIPERIDIN 4 YL](3,4 DICHLOROPHENYL)ETHANOIC ACID; [1 (TERT BUTOXYCARBONYL)PIPERIDIN 4 YL](4 CHLOROPHENYL)ETHANOIC ACID; [1 (TERT BUTOXYCARBONYL)PIPERIDIN 4 YL](NAPHTHALEN 2 YL)ETHANOIC ACID; AMPHOPHILE; CATIONIC AMPHIPHILIC DRUG; MONOAMINE; PIPERIDINE DERIVATIVE; TERT BUTYL 4 [(3 CHLORO 4 FLUOROPHENYL)(CYANO)METHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [(3 CHLORO 4 FLUOROPHENYL)(CYANO)METHYLIDENE]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [(3 CHLOROPHENYL)(CYANO)METHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [(3 CHLOROPHENYL)(CYANO)METHYLIDENE]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [(4 CHLOROPHENYL)(CYANO)METHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [(4 CHLOROPHENYL)(CYANO)METHYLIDENE]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (3 CHLORO 4 FLUOROPHENYL) 2 HYDROXYETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (3 CHLOROPHENYL) 2 HYDROXYETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (3,4 DICHLOROPHENYL) 2 (DIMETHYLAMINO) 2 OXOETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (3,4 DICHLOROPHENYL) 2 ETHOXY 2 OXOETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (3,4 DICHLOROPHENYL) 2 HYDROXYETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (3,4 DICHLOROPHENYL) 2 METHOXY 2 OXOETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (3,4 DICHLOROPHENYL) 2 METHOXYETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [1 (4 CHLOROPHENYL) 2 HYDROXYETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [2 HYDROXY 1 (NAPHTHALEN 2 YL)ETHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [CYANO(3,4 DICHLOROPHENYL)METHYLIDENE]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [CYANO(NAPHTHALEN 2 YL)METHYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [CYANO(NAPHTHALEN 2 YL)METHYLIDENE]PIPERIDINE 1 CARBOXYLATE; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN LEVEL; DEPRESSION; DRUG DESIGN; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX;

MUS;

EID: 84879668118     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.05.025     Document Type: Article

References (27)

1. World Health Organization (WHO). Fact sheet No. 369: Depression, October, 2012. http://www.who.int/mediacentre/factsheets/fs369/en/index.html.
2. S.K. Kulkarni, and A. Dhir Expert Opin. Investig. Drugs 18 6 2009 767
3. J. Prins, B. Olivier, and S.M. Korte Expert Opin. Investig. Drugs 20 8 2011 1107
4. K. Golembiowska, M. Kowalska, and F.P. Bymaster Synapse 66 2012 435
5. M.J. Millan Neurotherapeutics 6 2009 53
6. P. Skolnick, P. Krieter, J. Tizzano, A. Basile, P. Popik, P. Czobor, and A. Lippa CNS Drug Rev. 12 2 2006 123
7. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and S.A. Lippa Life Sci. 73 2003 3175
8. Evaluation using in house data.
9. C log P value was calculated by Daylight Software. (C log P, version 4.82, Daylight Software, Daylight Chemical Information Systems, Inc., Aliso Viejo, CA; http://www.daylight.com).
10. Recent examples of mitigating these liabilities by reducing lipophilicity: J.G. Cumming, J.F. Bower, D. Waterson, A. Faull, P.J. Poyser, P. Turner, B. McDermott, A.D. Campbell, J. Hudson, M. James, J. Winter, and C. Wood Bioorg. Med. Chem. Lett. 22 2012 3895
11. I. Sato, K. Morihira, H. Inami, H. Kubota, T. Morokata, K. Suzuki, Y. Iura, A. Nitta, T. Imaoka, T. Takahashi, M. Takeuchi, M. Ohta, and S. Tsukamoto Bioorg. Med. Chem. 16 2008 8607
12. Piperidine moiety was occasionally found in substructure of CNS drugs (e.g., Paroxetine, Pethidine and Haloperidol).
13. S. Krishnamurthy, and H.C. Brown J. Org. Chem. 41 1976 3064
14. B.F. Bonini, M. Comes-Franchini, M. Fochi, G. Mazzanti, A. Alfredo Ricci, and G. Varchi Synlett 1998 1013
15. R. Netzer, A. Ebneth, U. Bischoff, and O. Pongs Drug Discovery Today 6 2001 78
16. M.H. Bridgland-Taylor, A.C. Hargreaves, A. Easter, A. Orme, D.C. Henthorn, M. Ding, A.M. Davis, B.G. Small, C.G. Heapy, N. Abi-Gerges, F. Persson, I. Jacobson, M. Sullivan, N. Albertson, T.G. Hammond, E. Sullivan, J.-P. Valentin, and C.E. Pollard J. Pharmacol. Toxicol. Methods 54 2006 189
17. X. Cao, T. Lee, M. Holmqvist, D. Mikhailov, Y. Ni, H. Zhang, C. Hogan, M.E. Digan, L. Urban, and G. Erdemli J. Pharmacol. Toxicol. Methods 64 2011 e8
18. S. Miyamoto, A. Matsumoto, I. Mori, and A. Horinouchi Toxicol. Mech. Methods 19 2009 477
19. P. Skolnik, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa Eur. J. Pharmacol. 461 2003 99
20. A.J. Eshleman, M. Carmolli, M. Cumbay, C.R. Martens, K.A. Neve, and A.J. Janowsky Pharmacol. Exp. Ther. 289 1999 877
21. QT prolongation was not observed in dog telemetry test by intravenous administration of compound (S)-3a.
22. L. Steru, R. Chermat, B. Thierry, and P. Simon Psychopharmacology 85 1985 367
23. F.P. Bymaster, W. Zhang, P.A. Carter, J. Shaw, E. Chernet, L. Phebus, D.T. Wong, and K.W. Perry Psychopharmacology 160 2002 353
24. P. Bonaventure, L. Kelly, L. Aluisio, J. Shelton, B. Lord, R. Galici, K. Miller, J. Atack, T.W. Lovenberg, and C.J. Dugovic Pharmacol. Exp. Ther. 321 2007 690
25. H.D. Flack Acta Cryst. A39 1983 876
26. A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M. Burla, G. Polidori, and M.J. Camalli Appl. Cryst. 27 1994 435
27. G.M. Sheldrick Acta Cryst. A64 2008 112